Obermatt
See Similar Stocks →

Mink Therapeutics

NAQ:INKT · US6036932019
BiotechnologyX-Small

360° View

no current rank
Price/Sales—
Price/Earnings51
Price/Book84
Dividend Yield—
Revenue Growth—
Profit Growth96
Capital Growth19
TSR 52w71
Leverage24
Liquidity85
Refinancing3
Combined—
Analyst Opinions100
Pro Holdings5
Opinion Changes50
Market Pulse17

Profile

CountryUSA
IndustryBiotechnology
SizeX-Small
TypePublic Company
ExchangeNASDAQCM
Founded2017
Employees26
Websiteminktherapeutics.com
ISINUS6036932019
Last UpdateApr 2, 2026
Index & Theme
ImmunologyStem Cell TherapyInflammationHematologyOncologyRespiratoryBiopharmaBiotechnologyManufacturingTherapeutics

Description

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development and manufacturing of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated disea…

Similar Stocks

The companies this stock is ranked against.

Compare Mink Therapeutics with its peers
Cartesian Therapeutics
NMQ:RNAC
20
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Legend Biotech
NSQ:LEGN
30
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Disc Medicine
NMQ:IRON
5
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nurix Therapeutics
NMQ:NRIX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Caribou Biosciences
NSQ:CRBU
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Apogee Therapeutics
NMQ:APGE
58
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →